標題: Titlebook: Endocrine Therapy of Breast Cancer IV; A. Goldhirsch Conference proceedings 1990 Springer-Verlag Berlin Heidelberg 1990 Hormonrezeptoren.O [打印本頁] 作者: FROM 時間: 2025-3-21 16:13
書目名稱Endocrine Therapy of Breast Cancer IV影響因子(影響力)
書目名稱Endocrine Therapy of Breast Cancer IV影響因子(影響力)學科排名
書目名稱Endocrine Therapy of Breast Cancer IV網(wǎng)絡公開度
書目名稱Endocrine Therapy of Breast Cancer IV網(wǎng)絡公開度學科排名
書目名稱Endocrine Therapy of Breast Cancer IV被引頻次
書目名稱Endocrine Therapy of Breast Cancer IV被引頻次學科排名
書目名稱Endocrine Therapy of Breast Cancer IV年度引用
書目名稱Endocrine Therapy of Breast Cancer IV年度引用學科排名
書目名稱Endocrine Therapy of Breast Cancer IV讀者反饋
書目名稱Endocrine Therapy of Breast Cancer IV讀者反饋學科排名
作者: Ingest 時間: 2025-3-21 23:32
osis and treatment of cancer. There are two main reasons why such an initiative was. considered necessary. Firstly, the teaching of oncology requires a rigorously multidisciplinary approach which is difficult for the Univer- sities to put into practice since their system is mainly disciplinary orien作者: candle 時間: 2025-3-22 04:24 作者: 愉快嗎 時間: 2025-3-22 07:44
Reproductive Diversity of Plants A remarkable feature of treatment with tamoxifen is the low incidence of side effects [1,3]. These clinical observations and the large body of evidence from the laboratory [6,7] have focussed clinical attention on long-term, or indefinite (treatment until relapse), adjuvant tamoxifen therapy [5,8–10].作者: 懲罰 時間: 2025-3-22 12:40
Floral Morphology and Sexuality,ls indicate that it is as effective as older treatments, for example, oe- strogens [2], but has fewer side effects. In premenopausal women, treatment with tamoxifen is equivalent in effectiveness to oophorectomy [3].作者: 特別容易碎 時間: 2025-3-22 13:09
Role of Oestrogen and Progestin in Human Mammary Carcinogenesis,cally-derived risk factors such as the protective effect of ovariectomy and increased risk of breast cancer in young women given diethylstilboestrol to prevent abortion [1,2]; and (c) the mitogenic effects of oestrogens on established breast cancer cell lines [5,6] and efficacy of antioestrogens in treating established breast cancer [7].作者: 特別容易碎 時間: 2025-3-22 19:28 作者: 鞏固 時間: 2025-3-22 22:16
Tamoxifen as an Agonist for Metastatic Breast Cancer,ls indicate that it is as effective as older treatments, for example, oe- strogens [2], but has fewer side effects. In premenopausal women, treatment with tamoxifen is equivalent in effectiveness to oophorectomy [3].作者: maroon 時間: 2025-3-23 01:26 作者: essential-fats 時間: 2025-3-23 06:41
https://doi.org/10.1007/978-1-4612-2866-0DNA ploidy, oncogenes, growth factor receptors, and some glycoproteins) are used for making therapeutic decisions [2]. At present, more than 60 prognostic parameters have been reported and can be classified into 4 main groups: patient characteristics, blood parameters, tumour characteristics and response to therapy (Table 2).作者: Seizure 時間: 2025-3-23 13:37 作者: 多樣 時間: 2025-3-23 14:25
Alesha Doan,J. Shoshanna Ehrlichnd deaths due to breast cancer in a population occur gradually over long periods of time from diagnosis. In contrast, other malignant diseases such as acute leukaemia or high- grade lymphomas have a much shorter natural history with a high rate of events occurring within weeks or months.作者: Preserve 時間: 2025-3-23 21:38 作者: Outspoken 時間: 2025-3-23 23:08
Alternative Methods for Describing Treatment Benefit Including Quality-of-Life Considerations,nd deaths due to breast cancer in a population occur gradually over long periods of time from diagnosis. In contrast, other malignant diseases such as acute leukaemia or high- grade lymphomas have a much shorter natural history with a high rate of events occurring within weeks or months.作者: generic 時間: 2025-3-24 02:20 作者: 追逐 時間: 2025-3-24 07:34 作者: 地名詞典 時間: 2025-3-24 13:19 作者: Adj異類的 時間: 2025-3-24 17:29 作者: Fibrillation 時間: 2025-3-24 21:19 作者: CRATE 時間: 2025-3-24 23:10 作者: 信條 時間: 2025-3-25 06:37 作者: angina-pectoris 時間: 2025-3-25 07:33 作者: 一致性 時間: 2025-3-25 13:54
Molecular Genetics of Steroid Hormone Receptors,equent growth of breast cancer cells are hormonally regulated, and elucidation of the mechanisms of these processes requires an understanding of the structure and function of hormonal receptors. Moreover, receptor determination in tumour biopsies has now been used for many years as a means of predic作者: kindred 時間: 2025-3-25 16:51
Prognostic Factors in Breast Cancer,selection of high- and low-risk patients. In the current discussion on the application of systemic adjuvant therapy in primary breast cancer, identification of high- and low-risk patients is a major issue [1]. Several classical (Table 1) and second generation prognostic factors (proliferation rate, 作者: Airtight 時間: 2025-3-25 23:58
Long-Term Tamoxifen Therapy: An Appropriate Chemosuppressive Treatment for Breast Cancer,acy as an adjuvant in node-positive disease [3,4] and increasing numbers of node-negative breast cancer patients are being treated with tamoxifen [5]. A remarkable feature of treatment with tamoxifen is the low incidence of side effects [1,3]. These clinical observations and the large body of eviden作者: 不法行為 時間: 2025-3-26 00:56
Tamoxifen as an Agonist for Metastatic Breast Cancer,e-effect profile, it has become the treatment of first choice for patients with locally advanced and metastatic breast cancer. Phase III clinical trials indicate that it is as effective as older treatments, for example, oe- strogens [2], but has fewer side effects. In premenopausal women, treatment 作者: geometrician 時間: 2025-3-26 05:18
Adjuvant Chemotherapy in Premenopausal Breast Cancer Patients is Effective by Means Other than Ovar, we analysed the incidence of amenorrhoea and its association with outcome in a cohort of 1127 premenopausal women included in a randomised trial. There were 4 distinct subpopulations defined by nodal status and therapy: in a group with node-negative disease (552 patients), one course of cytotoxic 作者: Modicum 時間: 2025-3-26 12:07 作者: 管理員 時間: 2025-3-26 15:03
https://doi.org/10.1007/978-3-642-75948-2Hormonrezeptoren; Ovarsuppression; breast cancer; cancer; carcinogenesis; cell; chemotherapy; genetics; horm作者: interlude 時間: 2025-3-26 19:13 作者: Acetabulum 時間: 2025-3-26 21:33 作者: LURE 時間: 2025-3-27 05:11 作者: 畢業(yè)典禮 時間: 2025-3-27 05:31
https://doi.org/10.1007/978-1-4612-2866-0selection of high- and low-risk patients. In the current discussion on the application of systemic adjuvant therapy in primary breast cancer, identification of high- and low-risk patients is a major issue [1]. Several classical (Table 1) and second generation prognostic factors (proliferation rate, 作者: 討好女人 時間: 2025-3-27 11:07
Reproductive Diversity of Plantsacy as an adjuvant in node-positive disease [3,4] and increasing numbers of node-negative breast cancer patients are being treated with tamoxifen [5]. A remarkable feature of treatment with tamoxifen is the low incidence of side effects [1,3]. These clinical observations and the large body of eviden作者: 脆弱吧 時間: 2025-3-27 15:18 作者: recede 時間: 2025-3-27 19:29
Reproductive Endocrinology and Infertility, we analysed the incidence of amenorrhoea and its association with outcome in a cohort of 1127 premenopausal women included in a randomised trial. There were 4 distinct subpopulations defined by nodal status and therapy: in a group with node-negative disease (552 patients), one course of cytotoxic 作者: 就職 時間: 2025-3-28 00:07
Alesha Doan,J. Shoshanna Ehrlichpercent of these patients have operable disease, i.e., after removal of the primary tumour and the ipsilateral axilla the patient is rendered free of macroscopic disease and thus is potentially cured. More than 60% of these patients are estimated, however, to die of metastatic breast cancer. From a 作者: Flinch 時間: 2025-3-28 02:18
Making the Decision to Have a Child,The decision to offer adjuvant systemic therapy to a patient with primary breast cancer depends on the expected benefit in terms of improved recurrence-free survival and overall survival in relation to the expected harm in terms of side effects, socioeconomic costs, and possible overtreatment.作者: Trabeculoplasty 時間: 2025-3-28 09:57 作者: AMITY 時間: 2025-3-28 10:57 作者: 漂白 時間: 2025-3-28 14:48
Prognostic Factors in Node-Negative Breast Cancer Patients,The decision to offer adjuvant systemic therapy to a patient with primary breast cancer depends on the expected benefit in terms of improved recurrence-free survival and overall survival in relation to the expected harm in terms of side effects, socioeconomic costs, and possible overtreatment.作者: 地殼 時間: 2025-3-28 22:27 作者: Foolproof 時間: 2025-3-29 01:50
Adjuvant Systemic Therapy in Node-Negative Breast Cancer,After more than 40 years of experience with systemic adjuvant therapy and more than 100 reported randomised adjuvant trials in breast cancer, it can be stated that adjuvant treatment significantly changes the natural course of this systemic and chronic disease.作者: 厭惡 時間: 2025-3-29 03:51
978-3-642-75950-5Springer-Verlag Berlin Heidelberg 1990作者: 無可非議 時間: 2025-3-29 08:02 作者: 阻撓 時間: 2025-3-29 14:28
0170-8643 e of control theory and systems thinking in developing the t.Cyber-physical systems (CPS) involve deeply integrated, tightly coupled computational and physical components. These systems, spanning multiple scientific and technological domains, are highly complex and pose several fundamental challenge作者: innate 時間: 2025-3-29 15:48 作者: chondromalacia 時間: 2025-3-29 23:35
